337 related articles for article (PubMed ID: 24682844)
1. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James SK; Bach RG; Becker RC; Budaj A; Heras M; Himmelmann A; Horrow J; Katus HA; Lassila R; Morais J; Nicolau JC; Steg PG; Storey RF; Wojdyla D; Wallentin L;
Eur Heart J; 2014 Jun; 35(23):1541-50. PubMed ID: 24682844
[TBL] [Abstract][Full Text] [Related]
2. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Cornel JH; Becker RC; Goodman SG; Husted S; Katus H; Santoso A; Steg G; Storey RF; Vintila M; Sun JL; Horrow J; Wallentin L; Harrington R; James S
Am Heart J; 2012 Sep; 164(3):334-342.e1. PubMed ID: 22980299
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
[TBL] [Abstract][Full Text] [Related]
4. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.
Pollack CV; Davoudi F; Diercks DB; Becker RC; James SK; Lim ST; Schulte PJ; Spinar J; Steg PG; Storey RF; Himmelmann A; Wallentin L; Cannon CP;
Clin Cardiol; 2017 Jun; 40(6):390-398. PubMed ID: 28598510
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Kang HJ; Clare RM; Gao R; Held C; Himmelmann A; James SK; Lim ST; Santoso A; Yu CM; Wallentin L; Becker RC;
Am Heart J; 2015 Jun; 169(6):899-905.e1. PubMed ID: 26027629
[TBL] [Abstract][Full Text] [Related]
7. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Harding SA; Holley A; Wilkins B; Fairley S; Simmonds M; Larsen PD
Intern Med J; 2017 Nov; 47(11):1298-1305. PubMed ID: 28857445
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
[TBL] [Abstract][Full Text] [Related]
10. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Lindholm D; Varenhorst C; Cannon CP; Harrington RA; Himmelmann A; Maya J; Husted S; Steg PG; Cornel JH; Storey RF; Stevens SR; Wallentin L; James SK
Eur Heart J; 2014 Aug; 35(31):2083-93. PubMed ID: 24727884
[TBL] [Abstract][Full Text] [Related]
13. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
[TBL] [Abstract][Full Text] [Related]
16. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
[TBL] [Abstract][Full Text] [Related]
17. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Cooper A; Cairns R; Cannon CP; Wallentin L
Eur Heart J; 2011 Dec; 32(23):2945-53. PubMed ID: 21804104
[TBL] [Abstract][Full Text] [Related]
18. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
19. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
20. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL
Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
